The Pharma Data

NOVEMBER 6, 2020

They also examined reported family income, the highest level of guardian-completed education and community poverty level, collectively called social determinants of health, using zip codes and the 2014–2018 American Community Survey. At its core is Hospital for Special Surgery, nationally ranked No. SOURCE Hospital for Special Surgery.

Nurses 52

Nurses Hospitals Disease Therapies 52

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases. link] Zhu et al.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

NOVEMBER 23, 2020

of the University Hospitals of Derby and Burton NHS Foundation Trust in the United Kingdom, and colleagues found that small standard slit-lamp breath shields offer some protection against COVID-19 infection transmission but are not as effective as larger slit-lamp breath shields, especially against coughs. In one study, Ali Poostchi, M.D.,

Clinical Trials 52

Clinical Trials Hospitals International Therapies 52

The Pharma Data

JUNE 28, 2021

Million People in Japan[1],[2] Aimovig is the First and Only Approved Treatment in Japan to Block the Calcitonin Gene-Related Peptide Receptor (CGRP-R) That Plays an Important Role in Migraine[3] Aimovig Continues to be the Most Utilized Anti-CGRP Pathway Therapy, With More Than Half a Million Patients Prescribed Worldwide[4].

Treatment 52

Treatment Disease Clinical Trials Hospitals 52

The Pharma Data

DECEMBER 17, 2020

Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. Thérin is the president of Advanced Therapies at Siemens Healthineers. Edris joined SpringWorks in 2018 as CBO to lead the company’s corporate strategy, business development and intellectual property efforts.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

The Pharma Data

SEPTEMBER 5, 2021

. “This new analysis from NAVIGATOR is exciting for the up to one in five severe asthma patients who have comorbid nasal polyps,” said Professor Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, UK, the principal investigator of the NAVIGATOR trial. and AstraZeneca will record sales in Canada.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

DECEMBER 13, 2020

Professor Jie Wang from Cancer Hospital Chinese Academy of Medical Sciences is the leading principal investigator for the study. On December17 ,2018, Toripalimab obtained conditional approval from the NMPA, for the 2 nd line treatment of patients with unresectable or metastatic melanoma. SHANGHAI, China, Dec.

Treatment 40

Treatment Clinical Trials Biosimilars Pharmaceutical Companies 40

The Pharma Data

JANUARY 21, 2021

Prior to joining Labcorp, she held multiple appointments with The Children’s Hospital of Philadelphia, including Patient Safety Officer, chief of the Division of Transfusion Medicine and Vice-Chief of Pathology and Laboratory Medicine. since May 2018. She succeeds Dot Adcock, who retired. He previously served as president and COO.

Laboratories 52

Laboratories Pharmaceuticals Clinical Development Engineering 52

The Pharma Data

NOVEMBER 17, 2020

Dr. Anderson moved to North Carolina to work at Presbyterian Hospital under the direction of Dr. Klaus Wiemer in 1992. She speaks nationally and internationally on how cancer and autoimmune disease therapies affect reproductive health and fertility, ovarian aging, primary ovarian insufficiency and genetics. Karen R. .

Laboratories 52

Laboratories Nurses Doctors International 52

The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration Breakthrough Therapy Designation granted to tezepelumab in Sept. 2018 for patients with severe asthma, without an eosinophilic phenotype. 6-8 Patients with severe asthma account for twice as many asthma-related hospitalizations. Tezepelumab was very well tolerated in patients with severe asthma.

Trials 52

Trials Production Clinical Trials Government 52

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

2018) , Arnold Partnership v. The PTO’s not-even-specious-argument, citing what certainly appears to us to be absolutely irrelevant case law, such as Novartis AG v. Ezra Ventures LLC, 909 F.3d 3d 1367 (Fed. Rogan , 246 F. 2d 460 (E.D. 2003) , and Biogen lnt’l v. Banner Life Sciences LLC, 956 F.3d 3d 1351 (Fed. Patent Nos.

FDA Approval 59

FDA Approval FDA Production Therapies 59

The Pharma Data

NOVEMBER 10, 2020

Additionally, oral capsules provide the convenience of home use, and increase patient compliance by eliminating the need for infusions in a clinic or hospital setting. Grand View Research August 2018 ( [link] ). Parexel is focused on supporting the development of innovative therapies to improve patient health. da Cunha, A.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

Broad Institute

MAY 2, 2024

In 2018, she graduated with a bachelor’s degree in computer science and biology and joined the lab of Gad Getz at the Broad Institute of MIT and Harvard to complete her master’s. In undergrad, I thought about going to medical school, but I didn’t want to work in a hospital. She didn’t want a sport to conflict with her academics.

Science 124

Science Medical Schools Hospitals Disease 124

The Pharma Data

AUGUST 19, 2020

Basildon University Hospital has been told its maternity services were inadequate after a whistleblower’s fears sparked a surprise inspection. A Care Quality Commission (CQC) report rated the unit at Basildon University Hospital as inadequate with “failings” found in six other serious cases. Image copyright.

Hospitals 52

Hospitals Doctors Therapies 52

The Pharma Data

JULY 8, 2021

Tezepelumab was granted an FDA Breakthrough Therapy Designation for patients with severe asthma without an eosinophilic phenotype in September 2018. 2,6,9) Patients with severe uncontrolled asthma have twice the risk of asthma-related hospitalizations.(10,11) About Severe Asthma. Globally, there are approximately 2.5

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

MARCH 3, 2022

The FDA’s Breakthrough Therapy Designation is designed to expedite the development and review of drugs and vaccines that are intended to treat or prevent serious conditions and preliminary clinical evidence indicates that the drug or vaccine may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

Virus 52

Virus Vaccine Clinical Trials Trials 52

FDA Law Blog: Biosimilars

OCTOBER 17, 2023

FDA previously released the final guidance document in December 2018 outlining the program’s principles, features, designation criteria, and other considerations. Additionally, the 2022 draft guidance suggested the addition of a new section to the 2018 guidance on reducing disparities in health and healthcare.

Production 53

Production FDA Treatment Disease 53

The Pharma Data

OCTOBER 20, 2020

News’ Best Hospitals for Cancer list. In hopes to advance the best and brightest, MD Anderson, in partnership with The Focus Fund GP, has launched the Cancer Focus Fund to propel compelling investigational cancer therapies from preclinical development through Phase II clinical trials. In 2018 , there were nearly 600,000 cancer deaths.

Clinical Trials 52

Clinical Trials Therapies Pharma Companies Trials 52

The Pharma Data

JUNE 26, 2021

Current guidelines are limited and recommend treating pediatric patients with or at risk for reoccurring blood clots with standard anticoagulant therapy, which often requires painful injections, dietary restrictions and regular laboratory monitoring. EINSTEIN-Jr is the largest pediatric study completed to date for the treatment of VTE.

Doctors 52

Doctors Hospitals Treatment Clinical Trials 52

The Pharma Data

JUNE 29, 2021

Importantly, people with NMOSD now have the flexibility to administer treatment at home, which may alleviate the need to travel for hospital appointments.”. The Phase III SAkuraSky study evaluated the efficacy and safety of ENSPRYNG in combination with baseline immunosuppressive therapy in adults and adolescents with NMOSD.

Treatment 52

Treatment Therapies Disease Clinical Development 52

The Pharma Data

APRIL 17, 2021

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs. We are committed to expanding our presence in China and working with the MS community to address unmet medical needs through innovative therapies and solutions.”.

Treatment 52

Treatment Clinical Trials Disease Trials 52

The Pharma Data

SEPTEMBER 30, 2021

1 Illness coded as RSV specific bronchiolitis was found to be the leading explanation for hospitalization in infants under 12 months, consistent with a study of pediatric hospitalizations between 1997 and 2000.2 Poster presentation number 1137. public speaking number 1106281.*.

Vaccine 52

Vaccine Research Virus Disease 52

The Pharma Data

APRIL 23, 2021

European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. Hormone replacement therapy for endocrinopathies should be instituted as warranted.

Therapies 40

Therapies Treatment Licensing Licensing 40

The Pharma Data

OCTOBER 30, 2020

Previously approved under an Emergency Use Authorization (EUA), Veklury is now fully cleared for the treatment of hospitalized patients with COVID-19. hospitals. A revised EUA for the unapproved use of Veklury is in effect for hospitalized pediatric patients less than 12 years of age weighing at least 3.5

FDA Approval 52

FDA Approval Hospitals Treatment FDA 52

The Pharma Data

JUNE 18, 2021

On September 20, 2018, Pfizer announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older. October 24th, 2018. Stockholm: ECDC; 2018. Lancet Infect Dis. 2018;18(4):441-451. CAPA study.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

NOVEMBER 8, 2020

from the Hematology Department of Peking University People’s Hospital, are the principal investigators of these studies. Following the data releases in 2018 and 2019, this will be the third time that Ascentage Pharma has presented updated clinical data of HQP1351 at the ASH Annual Meeting. SUZHOU, China and ROCKVILLE, Md. ,

Trials 40

Trials Drugs FDA Therapies 40

Agency IQ

APRIL 19, 2024

Patients frequently receive up to four therapies at once and go through multiple prolonged courses of treatment to keep recurrence and progression at bay. Commonly combined treatment options include antineoplastics (chemotherapies), radiation therapy, corticosteroids, immunomodulators, proteasome inhibitors, and monoclonal antibodies.

FDA 40

FDA Disease Trials Clinical Trials 40

The Pharma Data

NOVEMBER 19, 2020

The study data came from a prospective study of participants at Rutgers and affiliated hospitals during the early phase of the pandemic. The study evaluated 546 healthcare works with direct patient exposure at two hospitals in New Jersey and 283 non-healthcare workers that did not have direct patient contact.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

OCTOBER 25, 2020

. The case report of a patient with SCD treated with voxelotor after presenting with a significant drop in hemoglobin, who was not responsive to transfusion with red blood cells in association with hospitalization for COVID-19. 2010;376(9757):2018-2031. GBT Time: 11 a.m. GBT Time: 11 a.m. 4 – 7.

Treatment 40

Treatment Disease FDA FDA Approval 40

The Pharma Data

OCTOBER 28, 2020

Indeed, nine of 12 ventilator-dependent adult patients with COVID-19 ARDS who received two doses of remestemcel-L under emergency compassionate use at New York’s Mt Sinai Hospital were successfully discharged within a median of 10 days. It also provided a financial report for the first quarter ended September 30, 2020.

Treatment 40

Treatment Trials Disease Production 40

The Pharma Data

JANUARY 7, 2021

The drugs — called fluoroquinolones — have been a mainstay of antibiotic therapy for decades. Food and Drug Administration issued a warning in 2018, saying people at high risk of aortic aneurysm should avoid fluoroquinolones. If that weakened tissue ruptures, it can cause fatal bleeding.

Doctors 52

Doctors Research Hospitals FDA 52

Drug Target Review

DECEMBER 28, 2023

In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. Involving more than 250 investigators based at 19 hospital sites across the UK, the study has analysed genetic signatures in lung tumours, tracking how they have evolved over the past nine years in more than 815 patients.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

JANUARY 13, 2021

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. “In We are grateful to have a new treatment available in the front-line setting for patients with advanced squamous non-small cell lung cancer,” said Jie Wang, M.D., Accessed December 2020. v Zhang, T., Tang, Z., … Li, K.

Production 52

Production Trials Clinical Trials Treatment 52

The Pharma Data

JUNE 18, 2021

. “These data add to the overall body of evidence that patients treated with ibrutinib can achieve extended progression-free survival and overall survival when used as a first-line therapy,” said Paul M. Single-agent ibrutinib was the most common treatment across line of therapy at enrollment. Barr , M.D., IMBRUVICA ®.

FDA Approval 40

FDA Approval Treatment Therapies FDA 40

Agency IQ

OCTOBER 6, 2023

In a first, FDA tackles treatments for stimulant use disorder A new draft guidance from the FDA gives developers a roadmap to advance the development of novel therapies to address stimulant use disorders. Regulatory context FDA held a workshop in December 2019 to discuss development of substance use disorder therapies. What’s next?

FDA 40

FDA Treatment Production Trials 40

The Pharma Data

NOVEMBER 4, 2020

“We are excited to be nearing the EMA’s regulatory decision on VASCEPA and are busy preparing for our anticipated commercial launch in Europe, where there is a large and growing opportunity for Amarin to bring this proven effective therapy to the millions of patients at high risk for cardiovascular events. 500 mg/dL) hypertriglyceridemia.

Production 40

Production Trials Disease FDA 40

Codon

JULY 14, 2024

While this departs from the reductionist, single-component therapies that have dominated transfusion medicine since World War II, emerging data underscores that whole blood transfusions—blood with all its parts—yield better outcomes following severe blood loss than transfusions involving discrete blood components. Always free.

Production 143

Production Clinical Trials Trials Therapies 143